Veracyte Stock Fair Value Calculator – Veracyte Receives Average ‘Moderate Buy’ Recommendation from Brokerages
November 4, 2023
🌥️Trending News
Veracyte ($NASDAQ:VCYT), Inc. recently received an average recommendation of “Moderate Buy” from brokerages, according to a consensus compiled by Zacks Investment Research. Veracyte is a genomic diagnostics company that offers molecular tests to diagnose conditions such as cancer and thyroid disease. The company’s testing solutions are designed to improve patient care while reducing the cost of health care. Veracyte collects and analyzes samples from patients, which are then used to inform diagnosis and treatment decisions.
Veracyte’s tests have been used to diagnose thousands of patients and have been validated through large-scale clinical studies. The company has a strong focus on using science and technology to provide accurate results, which has helped it become a trusted resource for physicians and patients alike.
Share Price
On Monday, VERACYTE Inc. (NYSE: VCYT) received an average ‘Moderate Buy’ recommendation from brokerages. This news was followed by a jump in the company’s stock price, with shares opening at $20.1 and closing at $20.2, up by 2.5% from its last closing price of 19.7. Analysts have generally given a positive outlook on the stock, citing its potential long-term returns due to its breakthrough gene expression technologies. Despite the positive analyst reports, investors remain cautious, as the company is yet to show strong financial performance in the past few quarters. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Veracyte. More…
| Total Revenues | Net Income | Net Margin |
| 328.63 | -29.06 | -9.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Veracyte. More…
| Operations | Investing | Financing |
| 31.27 | 2.78 | 3.66 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Veracyte. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.16k | 78.4 | 14.93 |
Key Ratios Snapshot
Some of the financial key ratios for Veracyte are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 42.9% | – | -9.4% |
| FCF Margin | ROE | ROA |
| 7.0% | -1.8% | -1.7% |
Analysis – Veracyte Stock Fair Value Calculator
At GoodWhale, we have conducted a detailed analysis of VERACYTE‘s financials. Using our proprietary Valuation Line, we have determined that the intrinsic value of VERACYTE shares is around $50.2. As such, investors should take this opportunity to buy VERACYTE stock as it is trading at an extremely attractive price. More…
Peers
The company’s competitors include Exact Sciences Corp, Invitae Corp, and NanoString Technologies Inc.
– Exact Sciences Corp ($NASDAQ:EXAS)
Exact Sciences Corp has a market cap of 7.56B as of 2022. The company’s ROE for the same year is -14.13%.
Exact Sciences Corp is a biotechnology company that focuses on the development of cancer detection tests. The company’s flagship product is Cologuard, a stool-based DNA test that can detect the presence of colorectal cancer.
– Invitae Corp ($NYSE:NVTA)
Invitae Corp is a biotechnology company that uses genetic information to help healthcare providers diagnose, treat and prevent disease. The company has a market cap of 689.82M as of 2022 and a Return on Equity of -120.15%.
– NanoString Technologies Inc ($NASDAQ:NSTG)
NanoString Technologies Inc is a molecular diagnostics company that develops and sells proprietary technologies and instruments for digital molecular profiling. The company has a market capitalization of 313.93 million as of 2022 and a return on equity of -87.4%. NanoString’s technology is based on a unique digital detection platform that can measure the expression of hundreds of genes simultaneously with high accuracy and precision. The company’s products are used in a variety of applications, including gene expression profiling, copy number variation analysis, single-nucleotide polymorphism genotyping, and mRNA quantification. NanoString’s products are sold to a diverse customer base, including academic research institutions, government laboratories, pharmaceutical and biotechnology companies, and diagnostic laboratories.
Summary
Veracyte, Inc. is a molecular diagnostics company focused on transforming diagnosis and treatment of patients with cancer and other diseases. Investment analysis of the company reveals an average recommendation of “Moderate Buy” from brokerages. Analysts highlight the company’s strong product portfolio, expansion of customer base and collaborations with leading healthcare providers, which are key drivers for its future growth.
However, some investors consider the company’s current valuation to be expensive, which might limit the upside potential. Overall, the company is expected to benefit from its innovative products and increased adoption in the healthcare industry.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
